Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A method to include the environmental hazard in drug prescribing.

Castensson S, Eriksson V, Lindborg K, Wettermark B.

Pharm World Sci. 2009 Feb;31(1):24-31. doi: 10.1007/s11096-008-9260-1. Epub 2008 Nov 27.

PMID:
19037740
2.

Evaluation of heat-conduction microcalorimetry in pharmaceutical stability studies. I. Precision and accuracy for static experiments in glass vials.

Angberg M, Nyström C, Castensson S.

Acta Pharm Suec. 1988;25(6):307-20. No abstract available.

PMID:
3245456
3.

X-ray conformational analysis of the potent thyroliberin analogue L-pyroglutamyl-beta-(2-thienyl)-L-analyl-L-prolinamide.

Stensland B, Castensson S.

J Mol Biol. 1982 Oct 25;161(2):257-68. No abstract available.

PMID:
6818354
4.

Occurrence of an insulin-like peptide in extracts of peripheral nerves of th cat and in extracts of human vagal nerves.

Uvnäs-Moberg K, Posloncec B, Hagerman M, Castensson S, Rubio C, Uvnäs B.

Acta Physiol Scand. 1982 Aug;115(4):471-7.

PMID:
6758491
5.

Synthesis and biological activities of thyroliberin (TRH) analogues with cysteine or cysteine derivatives in position one or two.

Björkman S, Castensson S, Isacson D, Karlsson JA, Sievertsson H, Bowers CY.

Acta Pharm Suec. 1980;17(6):297-306. No abstract available.

PMID:
6784445
8.

Conformational analysis of an analogue of thyroliberin (T.R.F.).

Bellocq AM, Castensson S, Sievertsson H.

Biochem Biophys Res Commun. 1977 Jan 24;74(2):577-83. No abstract available.

PMID:
402135
9.

The inhibitory action of analogs of thyrotropin-releasing hormone on the release of thyrotropin in vitro.

Castensson S, Björkman S, Sievertsson H.

Acta Pharm Suec. 1977;14(5-6):505-16. No abstract available.

PMID:
413330
10.

Peptides related to melanostatin (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.

Björkman S, Castensson S, Lindeke B, Sievertsson H.

Acta Pharm Suec. 1976;13(4):289-98. No abstract available.

PMID:
11638
11.

Thyrotropin and prolactin inhibitory studies by compounds related to the thyrotropin releasing hormone.

Sievertsson H, Castensson S, Andersson K, Björkman S, Bowers CY.

Biochem Biophys Res Commun. 1975 Oct 27;66(4):1401-7. No abstract available.

PMID:
811221
12.
13.

On the conformation of thyrotropin releasing hormone.

Sievertsson H, Castensson S, Bowers CY.

FEBS Lett. 1974 Jun 15;42(3):340-2. No abstract available.

14.

Studies on tetrapeptides related to thyrotropin releasing hormone and luteinizing hormone releasing hormone.

Sievertsson H, Castensson S, Lindgren O, Bowers CY.

Acta Pharm Suec. 1974 Feb;11(1):67-76. No abstract available.

PMID:
4205899
15.

Snythesis of analogs of the thyrotropin releasing hormone (TRH) and bioassays for TRH- and TRH-inhibiting activities.

Sievertsson H, Castensson S, Bowers CY, Friesen HG, Folkers K.

Acta Pharm Suec. 1973 Sep;10(4):297-308. No abstract available.

PMID:
4202399
16.

Bicyclic enamines. VI. Synthesis of gentianadine and the alkaloidal indoloquinolizidine skeleton.

Dolby J, Hasselgren KH, Castensson S, Nilsson JL.

Acta Chem Scand. 1972;26(6):2469-72. No abstract available.

PMID:
4673804
17.

Protein A from Staphylococcus aureus conversion of complement factor C3 by aggregates between IgG and protein A.

Stålenheim G, Castensson S.

FEBS Lett. 1971 Apr;14(2):79-81. No abstract available.

Supplemental Content

Loading ...
Support Center